Literature DB >> 27487857

Role of monocytes and endothelial cells in heparin-induced thrombocytopenia.

Daria Madeeva, Douglas B Cines, Mortimer Poncz, Lubica Rauova1.   

Abstract

Heparin-induced thrombocytopenia (HIT) is an autoimmune disorder characterised by thrombocytopenia and thrombosis. The mechanisms leading to platelet destruction are complex and the thrombotic complications of HIT appear to be due to multiple different intravascular targets. The dual binding of HIT antibodies to platelet surface PF4/GAG complexes and to FcγRIIA likely leads to both platelet clearance and to their direct activation. Monocytes and endothelial cells bind PF4 with higher avidity than platelets and are more resistant to competitive removal of surface-bound PF4 in the presence of heparin. Binding of HIT antibodies to PF4/glycosaminoglycan complexes on the surface on these cells leads to their activation and increased procoagulant activity. Binding of higher levels of PF4 released from activated platelets to the endothelium may lead to changes of the anticoagulant properties of the glycocalyx and target the endothelial cells for HIT antibodies. Pathogenic antibodies bound to endothelial cells further promote prothrombotic conditions by a mechanism that is independent of FcγR activation, yet not completely understood. A more detailed understanding of the role of monocytes and endothelium may identify new targets for intervention to mitigate the risk of thrombosis with less impact on systemic haemostasis than current approaches to treatment for this serious disorder.

Entities:  

Keywords:  FcγRIIA; PF4; Thrombosis; coated platelets; glycosaminoglycans

Mesh:

Substances:

Year:  2016        PMID: 27487857     DOI: 10.1160/TH16-02-0162

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Acute oxygenator failure: a new presentation of heparin-induced thrombocytopenia in a patient undergoing venovenous extracorporeal membrane oxygenation support.

Authors:  Robert A Ratzlaff; Juan G Ripoll; Lena L Kassab; Jose L Diaz-Gomez
Journal:  BMJ Case Rep       Date:  2016-12-16

2.  Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis.

Authors:  Kandace Gollomp; Amrita Sarkar; Sanjiv Harikumar; Steven H Seeholzer; Gowthami M Arepally; Kristin Hudock; Lubica Rauova; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2020-03-05       Impact factor: 25.476

Review 3.  COVID-19 versus HIT hypercoagulability.

Authors:  Theodore E Warkentin; Scott Kaatz
Journal:  Thromb Res       Date:  2020-08-10       Impact factor: 3.944

Review 4.  Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches.

Authors:  Jason B Giles; Elise C Miller; Heidi E Steiner; Jason H Karnes
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

5.  Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia.

Authors:  Jason B Giles; Heidi E Steiner; Jerome Rollin; Christian M Shaffer; Yukihide Momozawa; Taisei Mushiroda; Chihiro Inai; Kathleen Selleng; Thomas Thiele; Claire Pouplard; Nancy M Heddle; Michiaki Kubo; Elise C Miller; Kiana L Martinez; Elizabeth J Phillips; Theodore E Warkentin; Yves Gruel; Andreas Greinacher; Dan M Roden; Jason H Karnes
Journal:  Blood Adv       Date:  2022-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.